Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results

Executive Summary

Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.

Advertisement

Related Content

Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
Fostamatinib Skates Through OSKIRA-1 With Mixed Results
Fostamatinib Skates Through OSKIRA-1 With Mixed Results
Rigel’s High Science Bet
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
Rigel R&D Strategy Emphasizes Early Pipeline, Led By Asthma Drug
With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel